168 related articles for article (PubMed ID: 36700868)
1. Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020.
Adlhoch C; Delgado-Sanz C; Carnahan A; Larrauri A; Popovici O; Bossuyt N; Thomas I; Kynčl J; Slezak P; Brytting M; Guiomar R; Redlberger-Fritz M; Maistre Melillo J; Melillo T; van Gageldonk-Lafeber AB; Marbus SD; O'Donnell J; Domegan L; Gomes Dias J; Olsen SJ
Euro Surveill; 2023 Jan; 28(4):. PubMed ID: 36700868
[TBL] [Abstract][Full Text] [Related]
2. Neuraminidase inhibitors for critically ill children with influenza.
Louie JK; Yang S; Samuel MC; Uyeki TM; Schechter R
Pediatrics; 2013 Dec; 132(6):e1539-45. PubMed ID: 24276847
[TBL] [Abstract][Full Text] [Related]
3. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
[TBL] [Abstract][Full Text] [Related]
4. Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients.
Lee N; Leo YS; Cao B; Chan PK; Kyaw WM; Uyeki TM; Tam WW; Cheung CS; Yung IM; Li H; Gu L; Liu Y; Liu Z; Qu J; Hui DS
Eur Respir J; 2015 Jun; 45(6):1642-52. PubMed ID: 25573405
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.
Muthuri SG; Venkatesan S; Myles PR; Leonardi-Bee J; Al Khuwaitir TS; Al Mamun A; Anovadiya AP; Azziz-Baumgartner E; Báez C; Bassetti M; Beovic B; Bertisch B; Bonmarin I; Booy R; Borja-Aburto VH; Burgmann H; Cao B; Carratala J; Denholm JT; Dominguez SR; Duarte PA; Dubnov-Raz G; Echavarria M; Fanella S; Gao Z; Gérardin P; Giannella M; Gubbels S; Herberg J; Iglesias AL; Hoger PH; Hu X; Islam QT; Jiménez MF; Kandeel A; Keijzers G; Khalili H; Knight M; Kudo K; Kusznierz G; Kuzman I; Kwan AM; Amine IL; Langenegger E; Lankarani KB; Leo YS; Linko R; Liu P; Madanat F; Mayo-Montero E; McGeer A; Memish Z; Metan G; Mickiene A; Mikić D; Mohn KG; Moradi A; Nymadawa P; Oliva ME; Ozkan M; Parekh D; Paul M; Polack FP; Rath BA; Rodríguez AH; Sarrouf EB; Seale AC; Sertogullarindan B; Siqueira MM; Skręt-Magierło J; Stephan F; Talarek E; Tang JW; To KK; Torres A; Törün SH; Tran D; Uyeki TM; Van Zwol A; Vaudry W; Vidmar T; Yokota RT; Zarogoulidis P; ; Nguyen-Van-Tam JS
Lancet Respir Med; 2014 May; 2(5):395-404. PubMed ID: 24815805
[TBL] [Abstract][Full Text] [Related]
6. Neuraminidase inhibitors for preventing and treating influenza in children.
Wang K; Shun-Shin M; Gill P; Perera R; Harnden A
Cochrane Database Syst Rev; 2012 Jan; 1():CD002744. PubMed ID: 22258949
[TBL] [Abstract][Full Text] [Related]
7. Neuraminidase inhibitor resistance in influenza viruses.
Reece PA
J Med Virol; 2007 Oct; 79(10):1577-86. PubMed ID: 17705169
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Clinical Courses of Patients with Influenza after Neuraminidase Inhibitors Treatment: A Postcard Survey of the 2013-2014 Influenza Season in Osaka.
Yoshi N; Tocino Y; Fujioka M; Kureya Y; Asai K; Kimura T; Shinataku H; Hirata K
Osaka City Med J; 2016 Dec; 62(2):29-38. PubMed ID: 30550708
[TBL] [Abstract][Full Text] [Related]
9. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.
Meijer A; Rebelo-de-Andrade H; Correia V; Besselaar T; Drager-Dayal R; Fry A; Gregory V; Gubareva L; Kageyama T; Lackenby A; Lo J; Odagiri T; Pereyaslov D; Siqueira MM; Takashita E; Tashiro M; Wang D; Wong S; Zhang W; Daniels RS; Hurt AC
Antiviral Res; 2014 Oct; 110():31-41. PubMed ID: 25043638
[TBL] [Abstract][Full Text] [Related]
10. Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013.
Takemoto Y; Asai T; Ikezoe I; Yano T; Ichikawa M; Miyagawa S; Matsumoto J
Chemotherapy; 2013; 59(5):373-8. PubMed ID: 24821568
[TBL] [Abstract][Full Text] [Related]
11. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.
Monto AS; McKimm-Breschkin JL; Macken C; Hampson AW; Hay A; Klimov A; Tashiro M; Webster RG; Aymard M; Hayden FG; Zambon M
Antimicrob Agents Chemother; 2006 Jul; 50(7):2395-402. PubMed ID: 16801417
[TBL] [Abstract][Full Text] [Related]
12. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
Jefferson T; Jones MA; Doshi P; Del Mar CB; Heneghan CJ; Hama R; Thompson MJ
Cochrane Database Syst Rev; 2012 Jan; 1():CD008965. PubMed ID: 22258996
[TBL] [Abstract][Full Text] [Related]
13. Early Oseltamivir After Hospital Admission Is Associated With Shortened Hospitalization: A 5-Year Analysis of Oseltamivir Timing and Clinical Outcomes.
Katzen J; Kohn R; Houk JL; Ison MG
Clin Infect Dis; 2019 Jun; 69(1):52-58. PubMed ID: 30304487
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of antiviral treatment in preventing death in severe hospitalised influenza cases over six seasons.
Domínguez A; Romero-Tamarit A; Soldevila N; Godoy P; Jané M; Martínez A; Torner N; Caylà JA; Rius C;
Epidemiol Infect; 2018 May; 146(7):799-808. PubMed ID: 29606178
[TBL] [Abstract][Full Text] [Related]
15. The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: a multicenter, retrospective study.
Chen L; Han X; Li YL; Zhang C; Xing X
BMC Infect Dis; 2020 Aug; 20(1):628. PubMed ID: 32842994
[TBL] [Abstract][Full Text] [Related]
16. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.
Kumar D; Ison MG; Mira JP; Welte T; Hwan Ha J; Hui DS; Zhong N; Saito T; Katugampola L; Collinson N; Williams S; Wildum S; Ackrill A; Clinch B; Lee N
Lancet Infect Dis; 2022 May; 22(5):718-730. PubMed ID: 35085510
[TBL] [Abstract][Full Text] [Related]
17. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data.
Heneghan CJ; Onakpoya I; Jones MA; Doshi P; Del Mar CB; Hama R; Thompson MJ; Spencer EA; Mahtani KR; Nunan D; Howick J; Jefferson T
Health Technol Assess; 2016 May; 20(42):1-242. PubMed ID: 27246259
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan.
Ishiguro N; Koseki N; Kaiho M; Ariga T; Kikuta H; Oba K; Togashi T; Morita K; Inagawa A; Okamura A; Yamazaki S; Shida S; Konno M; Kawamura N; Ishizaka A; Takada K; Tsubakihara K; Nagano N; Shibata M; Furuyama H; Matsuzono Y; Koike A; Murashita M; Hatae Y; Arioka H; Yamanaka T; Watanabe T; Tabata Y; Kumita Y; Hazama K; Akutsu Y; Aoyagi H; Tobise C; Azuma K; Yasoshima K; Sawada Y; Uetsuji K; Tsuchida A; Tsuchiyama A; Yasuda K; Odagawa Y; Yoshioka M
J Infect Chemother; 2018 Jun; 24(6):449-457. PubMed ID: 29487035
[TBL] [Abstract][Full Text] [Related]
19. Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors.
Brown SK; Tseng YY; Aziz A; Baz M; Barr IG
Antiviral Res; 2022 Apr; 200():105280. PubMed ID: 35304163
[TBL] [Abstract][Full Text] [Related]
20. Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B.
Kawai N; Ikematsu H; Kawashima T; Maeda T; Ukai H; Hirotsu N; Iwaki N; Kashiwagi S
Influenza Other Respir Viruses; 2013 May; 7(3):448-55. PubMed ID: 22897904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
